Brief: Innovent Biologics Enters Global Strategic Collaboration With Pfizer For 12 Oncology Programs
29/05/2026 02:27
BRIEF-Innovent Biologics Enters Global Strategic Collaboration With Pfizer For 12 Oncology Programs May 29 (Reuters) - Innovent Biologics Inc 1801.HK:
ENTERS GLOBAL STRATEGIC COLLABORATION WITH PFIZER FOR 12 ONCOLOGY PROGRAMS
TO RECEIVE $650 MILLION UPFRONT, DEAL VALUE UP TO $10.5 BILLION
TO RECEIVE UP TO DOUBLE-DIGIT ROYALTIES ON SALES OF APPROVED PRODUCTS
Further company coverage: 1801.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innovent Biologics
See all newsChina emerges as obesity drug lab for Big Pharma
Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China (updated)
China emerges as obesity drug lab for Big Pharma
Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results (updated)
Refile: Pfizer raises 2026 forecast on strong demand for blood thinner Eliquis